Research To Practice | Oncology Videos

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hodgkin and Non-Hodgkin Lymphomas — Faculty Presentation 1: Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma — Dr Christopher Flowers CME information and select publications

Featuring perspectives from Drs Christopher Flowers and Laurie Sehn, including the following topics: • Introduction (0:00) • Treatment for Diffuse Large B-Cell Lymphoma (7:45) • Management of Hodgkin Lymphoma (35:33) • Follicular Lymphoma (41:57) • Caring for Patients with Mantle Cell Lymphoma (51:38) CME information and select publications

Featuring perspectives from Drs Jonathan Strosberg and Lori Wirth, including the following topics: Nontargeted Treatment for Thyroid Cancer Introduction (0:00) Case: A woman in her late 60s with poorly differentiated thyroid cancer initially treated with lenvatinib – Dr Wirth (6:05) NTRK Fusions in Thyroid Cancer Case: A woman in her early 60s with metastatic papillary thyroid cancer with an NTRK fusion who received repotrectinib – Eric Sherman, MD (13:27) Case: A man in his early 60s with metastatic papillary thyroid cancer with NTRK fusion who received larotrectinib – Dr Wirth (18:37) RET Mutations/Fusions in Thyroid Cancer Case: A man in his early 40s who presents with metastatic medullary thyroid cancer with a RET mutation – Dr Sherman (21:43) Case: A man in his early 40s with metastatic medullary thyroid cancer with a RET mutation who received selpercatnib – Dr Wirth (27:49) Somatostatin Analogs for Neuroendocrine Tumors (NETs) Case: A woman in her early 50s with a newly well-differentiated small-bowel NET and low-volume liver metastases – Pamela Kunz, MD (33:41) Management of Carcinoid Syndrome with NETs Cases: A man in his early 60s with a well-differentiated small-bowel NET with stable disease on octreotide who is now experiencing increasing diarrhea and a man in his early 60s who received telotristat ethyl for carcinoid syndrome diarrhea – Dr Kunz and Dr Strosberg (41:25) Von Hippel-Lindau-Associated Pancreatic NETs Case: A woman in her late 40s with von Hippel-Lindau syndrome and a pancreatic NET who received belzutifan – Dr Strosberg (49:42) Case: A man in his early 60s with a symptomatic, well-differentiated hypervascular pancreatic NET with bulky liver metastases – Dr Kunz (55:38) CME information and select publications

Featuring perspectives from Dr Noopur Raje, including the following topics: • Introduction (0:00) • Case: A man in his early 80s who presents with renal failure (creatine = 7) and standard-risk multiple myeloma (MM) — Swati Vishwanathan, MD (14:22) • Case: A man in his late 60s with a large sternal plasmacytoma — Warren S Brenner, MD (20:35) • Case: A man in his early 60s who presents with multiple bone lesions and t(4;14), (1q21+) MM — Hans Lee, MD (23:21) • Case: A man in his late 30s with standard-risk MM who receives RVd followed by autologous stem cell transplant and has been on maintenance lenalidomide for 3.5 years — Yanjun Ma, MD (32:32) • Case: An asymptomatic woman in her mid 60s with quadruple-refractory MM with multiple prior serious infections — Neil Morganstein, MD (40:38) • Faculty Survey (53:19) • Case: A woman in her mid 70s with MM who developed severe peripheral neuropathy from induction RVd — Ranju Gupta, MD (57:45) CME information and select publications

Featuring a slide presentation and related discussion from Dr Edward Garon, including the following topics: • Immune checkpoint inhibitor therapy for treatment-naïve advanced non-small cell lung cancer (NSCLC) without an actionable mutation (0:00) • Duration of immunotherapy in the frontline setting for NSCLC with no targetable mutation (13:43) • New treatment strategies for relapsed or refractory NSCLC with no targetable mutation (16:25) • Management of antibody-drug conjugate-associated toxicity (19:08) • Activity of antibody-drug conjugates alone or in combination with anti-PD-1 antibodies (26:18) CME information and select publications

Featuring an interview with Dr Edward Garon, including the following topics: Treatment of non-small cell lung cancer (NSCLC) today versus prior to the availability of immune checkpoint inhibitors (0:00) Current and emerging roles of antibody-drug conjugates in NSCLC (3:30) Optimal workup for patients presenting with metastatic NSCLC; role of biomarker assessment (5:02) Considerations for the addition of an anti-CTLA-4 antibody to the treatment regimen for NSCLC (17:30) Correlation between immune-related toxicity and the efficacy of immune checkpoint inhibitors (21:47) Case: A woman in her mid 60s with multiple comorbidities presenting with NSCLC with a KRAS G12A mutation, pleural effusion and extensive bone metastases (24:35) Case: A man in his mid 50s with a long smoking history presenting with squamous cell carcinoma of the lung (31:07) Case: A woman in her early 60s with NSCLC with an EGFR L858R mutation who is relapsing after treatment with multiple therapies (37:22) Language barriers leading to disparities in clinical trial enrollment (44:38) CME information and select publications

Featuring perspectives from Dr Srdan Verstovsek, including the following topics: Overview of current issues in the management of myeloproliferative neoplasms (MPN) (0:00) Treatment strategies for patients with myelofibrosis (MF) progressing after ruxolitinib (14:46) Correlation of molecular characterization and response to ruxolitinib in patients with MF (23:57) Rationale for and efficacy with combined inhibition of Bcl-2 and Bcl-xL for MPN (44:38) Targeting calreticulin mutations for MPN (52:02) Advances in the management of polycythemia vera (57:54) Developments in the care of patients with essential thrombocythemia (1:04:43) Future directions in the clinical care of patients with MPN (1:12:46) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gynecologic Oncology — Faculty Presentation 2: Endometrial and Cervical Cancer — Dr Krishnansu Tewari CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gynecologic Oncology — Faculty Presentation 1: Ovarian Cancer — Dr Kathleen Moore CME information and select publications

Featuring perspectives from Drs Michael Birrer and Kathleen Moore, including the following topics: Gynecologic Oncology Introduction (0:00) Ovarian Cancer PARP inhibitors as primary maintenance (8:11) PARP inhibitors for recurrent and metastatic disease (19:04) Antibody-drug conjugates: Mirvetuximab soravtansine; upifitamab rilsodotin (31:39) Endometrial Cancer Immunotherapy for metastatic disease (43:49) Selinexor as maintenance therapy (51:33) Other novel agents (56:52) Cervical Cancer Immunotherapy for metastatic disease and the antibody-drug conjugate tisotumab vedotin (1:01:00) CME information and select publications